Ultragenyx Pharmaceutical (RARE) Non Operating Income (2013 - 2017)
Ultragenyx Pharmaceutical (RARE) posted quarterly Non Operating Income of $4.5 million for Q3 2017, up 412.56% year-over-year from $876000.0 in Q3 2016, and down 19.3% quarter-over-quarter from $5.6 million in Q2 2017.
Ultragenyx Pharmaceutical (RARE) Non Operating Income (2013 - 2017) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Non Operating Income for 5 consecutive years, with $4.5 million the latest figure, recorded in Q3 2017.
- In Q3 2017, Non Operating Income rose 412.56% year-over-year to $4.5 million; the TTM figure through Sep 2017 stood at $11.0 million (up 189.18% YoY), while the FY2016 annual figure was $2.2 million, up 2.26% from the prior year.
- Non Operating Income retreated to $4.5 million in Q3 2017 per RARE's latest filing, from $5.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $5.6 million in Q2 2017 and bottomed at -$3.3 million in Q1 2014.
- Historically, Non Operating Income has averaged $619000.0 across 5 years, with a median of $355000.0 in 2015.
- Annual changes were most pronounced in 2015 — Non Operating Income jumped 5128.57% — and 2016, when it plunged 174.95%.
- Ultragenyx Pharmaceutical's Non Operating Income stood at -$1.8 million in 2013, then surged by 111.44% to $205000.0 in 2014, then surged by 357.56% to $938000.0 in 2015, then sank by 174.95% to -$703000.0 in 2016, then surged by 738.69% to $4.5 million in 2017.
- Business Quant data shows RARE's Non Operating Income at $4.5 million in Q3 2017, $5.6 million in Q2 2017, and $1.7 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 4.49 Mn |
| Jun 30, 2017 | 5.56 Mn |
| Mar 31, 2017 | 1.66 Mn |
| Dec 31, 2016 | -703,000.00 |
| Sep 30, 2016 | 876,000.00 |
| Jun 30, 2016 | 1.13 Mn |
| Mar 31, 2016 | 865,000.00 |
| Dec 31, 2015 | 938,000.00 |
| Sep 30, 2015 | 704,000.00 |
| Jun 30, 2015 | 355,000.00 |
| Mar 31, 2015 | 123,000.00 |
| Dec 31, 2014 | 205,000.00 |
| Sep 30, 2014 | -14,000.00 |
| Jun 30, 2014 | 76,000.00 |
| Mar 31, 2014 | -3.29 Mn |
| Dec 31, 2013 | -1.79 Mn |
| Sep 30, 2013 | -667,000.00 |